JPMorgan Chase & Co. Has Lowered Expectations for Revvity (NYSE:RVTY) Stock Price
by Teresa Graham · The Cerbat GemRevvity (NYSE:RVTY – Get Free Report) had its price target dropped by equities researchers at JPMorgan Chase & Co. from $96.00 to $90.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential downside of 8.80% from the stock’s current price.
A number of other research analysts have also recently issued reports on the stock. Stifel Nicolaus dropped their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a report on Wednesday. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Wells Fargo & Company increased their target price on shares of Revvity from $107.00 to $110.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $117.00 target price on shares of Revvity in a report on Wednesday. Finally, Evercore increased their target price on shares of Revvity from $112.00 to $118.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Four analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $107.73.
Read Our Latest Analysis on RVTY
Revvity Trading Down 0.4%
NYSE RVTY opened at $98.69 on Wednesday. The stock has a market capitalization of $11.03 billion, a P/E ratio of 47.22, a P/E/G ratio of 2.13 and a beta of 1.05. Revvity has a 52-week low of $81.22 and a 52-week high of $118.30. The firm has a 50-day moving average price of $90.30 and a 200 day moving average price of $96.90. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.37.
Revvity (NYSE:RVTY – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.04. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The firm had revenue of $711.12 million during the quarter, compared to analysts’ expectations of $704.07 million. During the same period in the prior year, the company posted $1.01 earnings per share. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Equities research analysts expect that Revvity will post 5.33 EPS for the current year.
Institutional Trading of Revvity
Large investors have recently modified their holdings of the business. Ascentis Independent Advisors acquired a new stake in shares of Revvity in the first quarter valued at approximately $29,000. CYBER HORNET ETFs LLC acquired a new stake in shares of Revvity in the second quarter valued at approximately $32,000. Cromwell Holdings LLC grew its position in shares of Revvity by 141.4% in the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after purchasing an additional 198 shares during the last quarter. MUFG Securities EMEA plc acquired a new stake in shares of Revvity in the second quarter valued at approximately $34,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Revvity in the second quarter valued at approximately $49,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.
More Revvity News
Here are the key news stories impacting Revvity this week:
- Positive Sentiment: TD Cowen raised its price target to $120 (from $115) and maintains a buy stance, implying ~21.6% upside versus current levels — a bullish analyst call that can support upside momentum. TD Cowen price target raise
- Positive Sentiment: Barclays raised its target to $105 from $95 (now equal weight), signaling a higher valuation view even while keeping a neutral stance — provides incremental positive signal on near-term upside. Barclays target raise
- Neutral Sentiment: Coverage roundups and analyst notes are highlighting Revvity alongside peers, offering mixed takes on valuation and execution; these summaries provide context but no clear consensus catalyst. Analysts Offer Insights
- Neutral Sentiment: Coverage on Revvity’s strategic moves — including a China exit and an EPS “reset” — frames a possible portfolio reorientation; implications for long-term margins and growth are strategic and not immediately decisive for the stock. China exit & EPS reset
- Neutral Sentiment: Deep-dive pieces emphasize portfolio pruning and AI-related investments shaping Revvity’s outlook; investors will watch execution and how investments translate to margin/organic growth. Q1 deep dive
- Negative Sentiment: JPMorgan cut its price target to $90 (from $96) and moved to a neutral rating, signaling downside risk (~8.8% below current levels) and adding selling pressure amid the mixed analyst actions. JPMorgan target cut
About Revvity
Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.
Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.